An Analysis From the SELECT Trial - COVID-19| ESC 2024

JACC This Week
30/08/2024 6 min
An Analysis From the SELECT Trial - COVID-19| ESC 2024

Listen "An Analysis From the SELECT Trial - COVID-19| ESC 2024"

Descargar episodio Ver en sitio original

Episode Synopsis

Harlan Krumholz, MD, FACC, JACC Editor-in-Chief, and Benjamin M. Scirica, MD, MPH, FACC, discuss the surprising benefits of semaglutide beyond weight loss and cardiovascular health from the SELECT trial, which investigated the effects of semaglutide on COVID-19 outcomes and non-cardiovascular deaths in patients with obesity and cardiovascular disease.

More episodes of the podcast JACC This Week

December 2, 2025: Global CVD 1990–2023: Trends, Risks, and the Road Ahead | JACC This Week 24/11/2025
November 25, 2025: Clonal Hematopoiesis, Alcohol and Blood Pressure, Long-Term Risk, and Emerging Biomarkers | JACC This Week 17/11/2025
November 18, 2025: Adiposity, Heart Failure, and the Future of Cardiometabolic Care | JACC This Week 10/11/2025
November 11, 2025: Precision, Place, and the Future of Cardiovascular Prediction | JACC This Week 03/11/2025
November 4, 2025: The 2025 Hypertension Guideline: A New Era in Blood Pressure Control | JACC This Week 28/10/2025
October 28.2025: How Low Should We Go? | JACC This Week 20/10/2025
October 21, 2025 - The Adipokine Hypothesis, Adipose-Cardiac Signaling, Sex Differences, Therapeutic Implications, and Diverse Populations | JACC This Week 13/10/2025
October 14, 2025 - Emerging Frontiers in Cardiovascular Medicine: From Certification Reform to Inflammation Targeting | JACC This Week 06/10/2025
October 7, 2025: AI in Scientific Writing and New Frontiers in Cardiovascular Care | JACC This Week 29/09/2025
Computable Quality, Community Screening, and TAVR Debate | JACC This Week 29/09/2025
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA